ArQule, Inc. (NASDAQ:ARQL)

CAPS Rating: 2 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Recs

0
Player Avatar biotek2893319b (< 20) Submitted: 10/11/2006 1:29:17 PM : Outperform Start Price: $4.40 ARQL Score: +29.37

A gamble

Featured Broker Partners


Advertisement